Literature DB >> 20636224

Pharmacokinetic evaluation of piperacillin-tazobactam.

Yoshiro Hayashi1, Jason A Roberts, David L Paterson, Jeffrey Lipman.   

Abstract

IMPORTANCE OF THE FIELD: Piperacillin-tazobactam is a frequently prescribed intravenous antibiotic for moderate to severe infections used in hospital settings because of its broad activity against many pathogenic bacteria including Pseudomonas aeruginosa. However, its pharmacokinetics (PK) can be significantly altered in a variety of states. AREAS COVERED IN THIS REVIEW: This article provides a comprehensive and critical review of the PK of piperacillin-tazobactam in different patient populations. The pharmacodynamics (PD) of piperacillin-tazobactam is also discussed. WHAT THE READER WILL GAIN: The importance of appropriate antibiotic dosing in the context of the global tendency for reduced susceptibility of bacteria, including P. aeruginosa is emphasized. The interrelationship between PK and PD is discussed to provide an understanding of methods for procuring dosing regimens that increase the likelihood of clinical success for individual patients. Alternative dosing regimens, which may include administration by extended or continuous infusion of piperacillin-tazobactam as a mechanism to increase the likelihood of pharmacodynamic target attainment, are described. TAKE HOME MESSAGE: Where piperacillin-tazobactam is required for treatment, applying knowledge of PK and PD characteristics can facilitate optimal outcomes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20636224     DOI: 10.1517/17425255.2010.506187

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  24 in total

Review 1.  Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses.

Authors:  Ibrahim El-Haffaf; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-04-20       Impact factor: 6.447

2.  Pharmacokinetics of Piperacillin in Critically Ill Australian Indigenous Patients with Severe Sepsis.

Authors:  Danny Tsai; Penelope Stewart; Rajendra Goud; Stephen Gourley; Saliya Hewagama; Sushena Krishnaswamy; Steven C Wallis; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

3.  Beta-lactams in continuous infusion for Gram-negative bacilli osteoarticular infections: an easy method for clinical use.

Authors:  Alba Ribera; Laura Soldevila; Raul Rigo-Bonnin; Fe Tubau; Ariadna Padullés; Joan Gómez-Junyent; Javier Ariza; Oscar Murillo
Journal:  Infection       Date:  2018-01-23       Impact factor: 3.553

4.  Building a Better Test for Piperacillin-Tazobactam Susceptibility Testing: Would that It Were So Simple (It's Complicated).

Authors:  Andrew Henderson; Romney Humphries
Journal:  J Clin Microbiol       Date:  2020-01-28       Impact factor: 5.948

5.  High target attainment for β-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied.

Authors:  H Woksepp; A Hällgren; S Borgström; F Kullberg; A Wimmerstedt; A Oscarsson; P Nordlund; M-L Lindholm; J Bonnedahl; L Brudin; B Carlsson; T Schön
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-11-04       Impact factor: 3.267

6.  Population Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study.

Authors:  Vesa Cheng; Mohd H Abdul-Aziz; Fay Burrows; Hergen Buscher; Young-Jae Cho; Amanda Corley; Arne Diehl; Eileen Gilder; Stephan M Jakob; Hyung-Sook Kim; Bianca J Levkovich; Sung Yoon Lim; Shay McGuinness; Rachael Parke; Vincent Pellegrino; Yok-Ai Que; Claire Reynolds; Sam Rudham; Steven C Wallis; Susan A Welch; David Zacharias; John F Fraser; Kiran Shekar; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2021-08-30       Impact factor: 5.191

7.  Using a Validated Population Pharmacokinetic Model for Dosing Recommendations of Continuous Infusion Piperacillin for Critically Ill Adult Patients.

Authors:  Ibrahim El-Haffaf; Romain Guilhaumou; Lionel Velly; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2022-03-28       Impact factor: 5.577

8.  Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.

Authors:  T W Felton; W W Hope; B M Lomaestro; J M Butterfield; A L Kwa; G L Drusano; T P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

9.  Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis.

Authors:  Paul Whitaker; Xiaoli Meng; Sidonie N Lavergne; Sabah El-Ghaiesh; Manal Monshi; Caroline Earnshaw; Daniel Peckham; Jimmy Gooi; Steve Conway; Munir Pirmohamed; Rosalind E Jenkins; Dean J Naisbitt; B Kevin Park
Journal:  J Immunol       Date:  2011-05-23       Impact factor: 5.422

Review 10.  Year in review 2010: Critical Care--Infection.

Authors:  Leonardo Pagani; Arash Afshari; Stephan Harbarth
Journal:  Crit Care       Date:  2011-12-05       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.